Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $40.67 Average PT from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given a consensus rating of “Hold” by the eleven research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $40.6667.

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. raised their price target on Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, January 6th. The Goldman Sachs Group cut their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a report on Thursday, November 20th. Leerink Partners increased their price objective on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, December 26th. HC Wainwright lifted their target price on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Finally, Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $28.26 on Friday. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00. The business has a fifty day moving average price of $28.10 and a 200-day moving average price of $33.07. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -3.97 and a beta of 0.89.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,932 shares of the firm’s stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total value of $79,427.88. Following the completion of the transaction, the insider directly owned 29,190 shares in the company, valued at $790,757.10. This trade represents a 9.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Krishnan Viswanadhan sold 2,959 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $27.80, for a total value of $82,260.20. Following the completion of the sale, the insider owned 5,141 shares in the company, valued at approximately $142,919.80. This represents a 36.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 36,262 shares of company stock worth $984,237 over the last three months. Corporate insiders own 4.93% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Bellevue Group AG increased its holdings in Agios Pharmaceuticals by 3.5% in the third quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after buying an additional 124,586 shares in the last quarter. State Street Corp boosted its stake in shares of Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after acquiring an additional 845,433 shares in the last quarter. Erste Asset Management GmbH grew its position in shares of Agios Pharmaceuticals by 1.4% during the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock valued at $76,343,000 after acquiring an additional 40,000 shares during the period. Wellington Management Group LLP grew its position in shares of Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after acquiring an additional 2,049,287 shares during the period. Finally, Commodore Capital LP increased its stake in shares of Agios Pharmaceuticals by 0.6% in the 3rd quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after purchasing an additional 13,287 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.